Search

Crinetics Pharmaceuticals Inc

Avatud

SektorTervishoid

83.86 0.05

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

83.67

Max

83.98

Põhinäitajad

By Trading Economics

Sissetulek

-5M

-128M

Müük

6.8M

11M

Aktsiakasum

-1.23

Kasumimarginaal

-1,191.029

Töötajad

594

EBITDA

-5M

-127M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+2.04% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. aug 2026

Turustatistika

By TradingEconomics

Turukapital

4.5B

8.9B

Eelmine avamishind

83.81

Eelmine sulgemishind

83.86

Uudiste sentiment

By Acuity

60%

40%

286 / 340 Pingereas Healthcare

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. juuli 2026, 23:56 UTC

Correlated Moves
News

Diamondback Energy gained during after-market hours, buoyed by strong revenue growth and a favorable market position, with shares peaking above Monday's close.

27. juuli 2026, 23:51 UTC

News
Event

UDR Inc reported second-quarter net income of $69.035 million. Shares declined in after-market trading amid concerns over flat revenue and rising costs.

27. juuli 2026, 23:51 UTC

News

L3Harris Technologies has secured Pentagon agreements to boost missile defense production, but shares are trading lower in after-market hours.

27. juuli 2026, 23:51 UTC

News
Social Media

Tesla Inc shares declined in after-market trading, continuing a trend of lower closes over the past four sessions amid analyst caution following its Q2 performance.

27. juuli 2026, 23:51 UTC

News

Rivian shares rise in after-market trading as analysts upgrade outlook and boost price target ahead of earnings report on July 30.

27. juuli 2026, 23:51 UTC

News

Cincinnati Financial Corp shares fell in after-market hours following second-quarter results that missed expectations for EPS and revenue. Earlier in the session, shares briefly rose.

27. juuli 2026, 23:51 UTC

News
Social Media

Cadence Design Systems shares are higher in after-market trading following strong Q2 results and an increase in full-year revenue guidance to $6.26 billion to $6.34 billion.

27. juuli 2026, 23:51 UTC

News
Social Media

Microstrategy shares declined in after-market hours following Peter Schiff's criticism of the company's Bitcoin yield, which fell significantly in recent months.

27. juuli 2026, 23:51 UTC

News

Accenture PLC shares are lower in after-market hours despite a $2 billion share repurchase program and a quarterly dividend announcement.

27. juuli 2026, 23:51 UTC

News

NIO shares rose in after-market trading, building on regular-session gains. Options activity showed bullish sentiment, with calls outpacing puts significantly.

27. juuli 2026, 23:51 UTC

News
Social Media
Correlated Moves

Micron Technology Inc shares declined in after-market trading following a report raising concerns about the company's growth potential and future demand for memory chips.

27. juuli 2026, 23:51 UTC

News
Social Media

Amkor Technology's shares declined in after-market trading following weaker-than-expected third-quarter revenue guidance despite strong second-quarter results and earnings.

27. juuli 2026, 23:42 UTC

News
Correlated Moves

Bitcoin is trading lower as easing geopolitical tensions reduce demand for safe-haven assets. Ethereum also declines, reflecting its correlation with Bitcoin's market movements.

27. juuli 2026, 23:42 UTC

Correlated Moves
News

Bitcoin is trading lower as easing geopolitical tensions reduce demand for safe-haven assets. Ethereum also declines amid similar market dynamics.

27. juuli 2026, 23:41 UTC

News
Correlated Moves

NBT Bancorp shares are higher in after-market trading following second-quarter results, which included net income of $53 million and a dividend increase to $0.40 per share.

27. juuli 2026, 23:41 UTC

News
Social Media

Brown & Brown Inc reported second-quarter revenues of $1.68 billion, missing expectations. Shares are trading lower in after-market hours following the mixed results.

27. juuli 2026, 23:41 UTC

News

OPKO Health reported second-quarter revenues of $163.5 million, surpassing expectations. The company also raised its full-year sales guidance, boosting shares in after-market trading.

27. juuli 2026, 23:41 UTC

News

International Paper shares are higher in after-market trading as CEO Andy Silvernail prepares to present at the Jefferies 2026 Industrials Conference on September 10.

27. juuli 2026, 23:41 UTC

News

Oil prices are higher in after-market hours, supported by reduced supply disruption concerns from the Middle East and gains in European markets.

27. juuli 2026, 23:31 UTC

News

Northwest Bancshares reported second-quarter adjusted EPS of $0.37 and revenue of $181.2 million, exceeding expectations. Shares are trading higher in after-market hours.

27. juuli 2026, 23:31 UTC

News
Social Media

Johnson & Johnson shares are higher in after-market trading following a proposed $5.5 billion settlement for ovarian talc litigation involving about 76,000 claims.

27. juuli 2026, 23:31 UTC

News
Social Media

ServiceNow shares rose during after-market hours as software stocks recovered. CEO Bill McDermott reported no slowdown in demand amid mixed social media sentiment on AI impacts.

27. juuli 2026, 23:26 UTC

News

Nucor Corporation reported second-quarter earnings of $1.16 billion, exceeding estimates. Shares are trading higher in after-market hours following the strong results.

27. juuli 2026, 23:16 UTC

News
Social Media

Intel Corp shares are lower in after-market hours following a $2.1 billion loss, despite a 25% revenue increase to $16.1 billion in Q2.

27. juuli 2026, 23:16 UTC

News

Dell Technologies Inc. shares are lower in after-market hours, continuing a trend from the previous three sessions amid a focus on AI-optimized infrastructure solutions.

27. juuli 2026, 23:16 UTC

News

Zoetis shares are lower in after-market hours following a class action lawsuit alleging securities fraud and reduced profit guidance to between $6.85 and $7.00 per share.

27. juuli 2026, 23:11 UTC

News

Albertsons Companies Inc shares are lower in after-market hours amid an investigation into potential securities law violations and a Q1 EPS miss of $0.42.

27. juuli 2026, 23:02 UTC

News
Social Media

Welltower reported strong Q2 results, raising full-year FFO guidance and increasing its dividend. Shares are trading higher in after-market hours.

27. juuli 2026, 23:02 UTC

News
Social Media

Sanmina Corp shares are lower in after-market trading despite strong Q3 results, as Q4 guidance fell short of consensus estimates.

27. juuli 2026, 23:02 UTC

News

GoPro Inc. will release its Q2 financial results on August 10, 2026, contributing to a higher after-market price as investors anticipate insights.

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

2.04% tõus

12 kuu keskmine prognoos

Keskmine 85.56 USD  2.04%

Kõrge 95 USD

Madal 80 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

14 ratings

2

Osta

12

Hoia

0

Müü

Sentiment

By Acuity

286 / 340 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat